Weight loss surgery may protect liver with MASH-related cirrhosis
Weight loss surgery significantly lowers the risk of serious liver complications among obese people with cirrhosis, or irreversible liver scarring and damage, due to metabolic…
News
Livmarli relieves itch in adolescents with Alagille syndrome: Analysis
Treatment with Livmarli (maralixibat) is effective for relieving itch in adolescents with Alagille syndrome, according to a new analysis of previous clinical trials.
HBV vaccine birth dose not tied to premature babies’ lung disease risk
Babies born extremely prematurely who were given a dose of the hepatitis B virus (HBV) vaccine within a day of being born were not…
Three-factor tool may predict response to UDCA in PBC: Study
A predictive tool that incorporates several blood biomarkers may help to identify primary biliary cholangitis (PBC) patients who are less likely to respond to treatment…
Genetic variant that raises ICP risk is protective against hepatitis B
A genetic variant unique to East Asians increases the risk of intrahepatic cholestasis of pregnancy (ICP) by more than 16 times, but it likely…
Lanifibranor improves liver health in MASH with diabetes in trial
Daily treatment with the investigational oral therapy lanifibranor — used alone or in combination with the diabetes medication Jardiance (empagliflozin) — led to improvements…
Stem-cell therapy during Kasai effective, safe in biliary atresia: Trial
Children with biliary atresia who received infusions of bone-marrow stem cells during a Kasai operation, a liver surgery that’s the main strategy for treating…
FDA grants breakthrough designation to hepatitis D treatment
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to brelovitug, a hepatitis D treatment that’s being developed by Bluejay…
Livdelzi approved in UK as PBC treatment for certain adults
Gilead Sciences’ Livdelzi (seladelpar) has been approved in the U.K. as a treatment for adults with primary biliary cholangitis (PBC), either in combination…
Bylvay, Kayfanda in EU, safely treats PFIC: Real-world study
In real-world use, Kayfanda (odevixibat) — available under the brand name Bylvay in the U.S. — lowered blood bile acid levels and eased…
